在患有COVID-19后疾病 (PYCNOVID) 的人群中Pycnogenol®的影响:单中心,安慰剂控制,四重盲,随机试验的研究协议
Thomas Radtke1, Lisa Künzi2, Julia Kopp2
1Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. thomas.radtke@uzh.ch.
Trials
|June 15, 2024
概括
这项研究调查了Pycnogenol®对COVID-19后病情 (PCC) 症状. 皮克诺日 (Pycnogenol®) 可能提供一种治疗方法,以缓解持续的PCC症状并改善患者的健康状况.
科学领域:
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 后COVID-19状态 (PCC) 影响了SARS-CoV-2感染后的很大一部分人.
- 缺乏有效的PCC治疗方法,需要进行干预研究.
- 松树皮提取物Pycnogenol®具有与PCC症状管理相关的抗炎和抗氧化特性.
研究的目的:
- 评估与安慰剂相比,Pycnogenol®在改善PCC患者患者报告的健康状况方面的疗效.
- 探索Pycnogenol®对各种PCC相关症状和健康结果的影响.
主要方法:
- 一个单中心,安慰剂控制,四重盲,随机化试验,涉及150名PCC患者.
- 参与者每天接受200毫克Pycnogenol®或安慰剂,持续12周.
- 主要终点:12周的感知健康状况 (EuroQol-Visual Analogue Scale);次要终点包括症状变化,生活质量和生物标志物.
主要成果:
- PYCNOVID试验是第一个评估Pycnogenol®对PCC的试验.
- 关于主要和次要终点的结果正在等待试验完成.
- 该研究的设计包括患者参与和强大的失明程序.
结论:
- 这项试验是首次调查Pycnogenol®对COVID-19后的状况.
- 如果证明有效,Pycnogenol®可能成为管理PCC症状的有价值的治疗选择.
- 需要进一步的研究来证实Pycnogenol®在PCC中的临床有效性和安全性.
相关概念视频
01:27Psychoneuroimmunology: Cardiovascular Disease
30
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
30
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:20COPD: Pathogenesis and Clinical Features
258
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
258
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
01:22Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
01:29Pneumonia II: Pathophysiology
253
The pathophysiology of pneumonia involves the following steps:
253